Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03090334
Other study ID # BDG-ETHIC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2017
Est. completion date December 2020

Study information

Verified date April 2019
Source University of Bologna
Contact Maddalena Giannella, MD, phD
Phone +39 0512143199
Email maddalena.giannella@unibo.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:

1. discontinue antifungal treatment based on negative (<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10

2. continue antifungal treatment according with attending physician's decision.


Description:

Primary objective:

Our objective is to establish whether a strategy based on beta-d-glucan (BG) assessment could achieve reduced antifungal consumption in patients with severe abdominal condition developing severe sepsis and septic shock without any impact on the outcome Secondary objectives i) Assess the accuracy of BG in the diagnosis of invasive candidiasis (IC) in in critically ill patients with a severe abdominal condition who develop severe sepsis or septic shock.

ii) Describe the changes over the time of BG value according with colonization status, infection or none the aforementioned events.

Material and Methods Study design: a multicenter, open label, randomized trial Population: all the patients with a severe abdominal condition who develop a severe sepsis or septic shock.

1. Inclusion Criteria:

1. adult (≥ 18 year) patients;

2. signed informed consent before surgical procedure;

3. severe sepsis or septic shock;

4. at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.

2. Exclusion criteria a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count < 200/mmc. f. patients with poor prognosis or unable to sign informed consent.

Procedures Pre-randomization procedures

At the time of patient enrollment (within 24 h from onset of severe sepsis/septic shock), a standardized diagnostic work-up must be performed including at least:

i) two sets of blood cultures; ii) 5 surveillance cultures (rectal swab, urine culture, pharyngeal swab, axillary swab, groin swab).

iii) in case of re-intervention or percutaneous drainage: Gram stain and culture of intra-abdominal samples; iv) serum BG determination. Antibiotic and antifungal empirical therapy should be started immediately after collection of microbiological samples according with a predefined standard of care (see appendix 1). Once completed this procedures patients will proceed to randomization.

Randomization Patient eligible for the study after the beginning of antifungal therapy will be randomized 1:1 to receive (Group A) a BG driven de-escalation strategy or (Group B) a course of antifungal treatment based on the care provider's decision.

In both groups, if cultures yield invasive candidiasis (see below) the patient will be managed in according with guidelines and excluded from the per-protocol analysis.

In both groups, BG determination will be repeated at day +3, +6 and +10 after starting antifungal therapy.

Randomization will be carried out providing closed envelopes to the participating centers immediately before the study onset.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2020
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- a. adult (= 18 year) patients; b. signed informed consent before surgical procedure; c. severe sepsis or septic shock; d. at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.

Exclusion Criteria:

- a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count < 200/mmc. f. patients with poor prognosis or unable to sign informed consent.

Study Design


Intervention

Diagnostic Test:
De-escalation
Antifungal therapy will be stopped according with BG results

Locations

Country Name City State
Italy Azienda Ospealiero Universitaria di Bologna Policlinico S.Orsola-Malpighi Bologna

Sponsors (1)

Lead Sponsor Collaborator
University of Bologna

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P, Rocca GD, Roilides E, Sganga G, Walsh TJ, Tascini C, Tumbarello M, Menichetti F, Righi E, Eckmann C, Viscoli C, Shorr AF, Leroy O, Petrikos G, De Rosa FG. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 2013 Dec;39(12):2092-106. doi: 10.1007/s00134-013-3109-3. Epub 2013 Oct 9. — View Citation

Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013 May;56(9):1284-92. doi: 10.1093/cid/cit006. Epub 2013 Jan 11. Review. — View Citation

Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012 Jun;54(12):1739-46. doi: 10.1093/cid/cis305. Epub 2012 Mar 15. — View Citation

Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med. 2014 Sep;40(9):1241-55. doi: 10.1007/s00134-014-3404-7. Epub 2014 Aug 5. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Antifungal consumption Days of antifungal consumption will be compared between the two groups 28 days
Primary Mortality 28-day mortality will be compared between the two groups 28 days
Primary Length of stay Length of stay in ICU will be compared between the two groups 28 days
Secondary Accuracy of BG sensitivity, specificity, positive predictive value, negative predictive value of BG in the diagnosis of invasive candidiasis 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT02977429 - Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery N/A
Completed NCT01250574 - Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
Recruiting NCT02191475 - Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock Phase 2/Phase 3
Recruiting NCT03163095 - Closed or Open Abdomen for the Management of Abdominal Sepsis N/A
Not yet recruiting NCT04903886 - Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae
Completed NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3
Completed NCT01414959 - Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients N/A
Recruiting NCT03815370 - A Non-Traumatic Binder for Temporary Abdominal Wall Closure N/A